Watch Ticker

Mainz Biomed N.V. Ordinary Shares

Go to Mainz Biomed N.V. Ordinary Shares Website

$1.31

-0.11 (-7.75%)

Live

Previous Close

$1.42

Day Range

$0 - $0

Previous Day Range

$1.35 - $1.555

Market Cap

$5.1 million USD

Day Vol.

Previous Day Vol.

664108

Currency

USD

Primary Exchange

Nasdaq

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal ca...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Mainz Biomed N.V. - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Mainz Biomed reported a 33% increase in lab network revenue, a 30% decrease in operating loss, and an 18% decrease in net loss in 2024. The company made progress with strategic partnerships and its next-generation colorectal cancer screening product.

Related tickers: MYNZ, TMO, DGX.

Read Full Article

N/A - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed, a molecular genetics diagnostic company, is committed to combating colorectal cancer (CRC) by advancing diagnostic solutions for early detection. The company's flagship product, ColoAlert, and its next-generation screening method, which combines mRNA biomarkers, the FIT test, and a proprietary AI algorithm, demonstrate high sensitivity and specificity for detecting advanced adenomas, highlighting the potential for early intervention and prevention.

Related tickers: MYNZ.

Read Full Article

Trending Tickers

Please sign in to view